Calypte 2005 das Megajahr ?
Seite 4 von 6 Neuester Beitrag: 15.08.05 03:06 | ||||
| Eröffnet am: | 27.01.05 15:21 | von: LuckyStrike | Anzahl Beiträge: | 142 |
| Neuester Beitrag: | 15.08.05 03:06 | von: Wahrheit | Leser gesamt: | 12.998 |
| Forum: | Hot-Stocks | Leser heute: | 16 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | | 5 | 6 > | ||||
junge, was wollt ihr an der börse?
und, schon nachgekauft?
muahahahha
ihr hättet eure kröten besser mal bei den paar ausressertrades gesichert...
nein , aber natürlich nicht....muhahahahahhahaha
und schon geht es wieder runter:
Time & Sales most recent next page
Rec. Time Action Price Volume
9:42:58 AM Ask 0.37 200
9:42:56 AM Trade 0.37 7600
9:42:50 AM Trade 0.37 2400
9:42:50 AM Ask 0.38 29500
9:42:38 AM Bid 0.36 5000
9:42:34 AM Ask 0.37 2400
9:42:32 AM Ask 0.38 9000
9:42:30 AM Trade 0.37 20000
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
wir haben dieses Posting wegen Verstoßes gegen die Forumrichtlinien aus dem ARIVA.DE-Diskussionsforum gelöscht.
Ihr ARIVA.DE-Team
...Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure....
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
sie müssen endlich mal anfangen, das zeug zu verkaufen, aber so werdet ihr quartal für quartal, jahr für jahr hingehalten.
Rec. Time Action Price Volume
11:48:52 AM Bid 0.37 13500
11:48:28 AM Bid 0.37 8500
11:47:36 AM Trade 0.37 1500
11:47:14 AM Ask 0.38 46500
11:45:22 AM Trade 0.37 500
11:44:08 AM Trade 0.37 1500
11:42:10 AM Trade 0.38 400
11:42:10 AM Ask 0.38 48000
11:38:16 AM Ask 0.38 48400
11:36:30 AM Bid 0.37 6000
11:36:26 AM Bid 0.37 3000